6月16日，Twist Bioscience盘中上涨5.51%，报85.245美元/股，成交额2742.73万美元，延续前一交易日强势表现。
消息面上，Canaccord Genuity近日给予Twist Bioscience买入评级，目标价90美元，显著高于市场共识目标价73.12美元。该目标价较当前股价仍有约5.6%上行空间，持续对股价形成提振。据FactSet统计，该股分析师平均评级为买入，本次投行给出的高于共识约23%的目标价为市场注入乐观预期。值得注意的是，近期公司内部人连续进行小规模减持操作，包括董事Leproust Emily M.及多位高管在6月初以约69-70美元区间卖出股份，但规模有限，未对市场情绪构成明显压制。
Twist Bioscience是一家合成生物学平台公司，开发基于硅芯片的DNA合成技术，服务于医疗健康、食品农业、工业化学品及数据存储等领域。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.